Innovation in Biological Indicator Evaluator Resistometer Vessel Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovation in Biological Indicator Evaluator Resistometer Vessel Technology
The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.


Pharmaceutical Technology


Conclusion


Figure 13
Operational parameters of the Fedegari are not identical to the Steris resistometers; however, data collected during this study demonstrated that the Fedegari vessel performs parametrically as a resistometer. Results from the various resistometers were comparable with respect to the measured resistance of the tested indicators. Less variation was obtained with the Fedegari BIER for all but the ampul BI. Slight differences in determined resistance between the BIER units are to be expected and are typical of replicate results from any single BIER unit. The Fedegari BIER provided equivalent performance to the more traditional BIER design in a more versatile and cost-effective system.

References

1. ANSI/AAMI/ISO 18472:2006, Sterilization of Health Care Product—Biological and Chemical Indicators: Test Equipment (International Organization for Standardization, Geneva, Switzerland).

2. ANSI/AAMI/ISO 11138-1:2006, Sterilization of Health Care Product—Biological Indicators, Part 1: General Requirements (International Organization for Standardization, Geneva, Switzerland).

James Agalloco is president of Agalloco & Associates (Belle Mead, NJ). Kurt McCauley is the research and development manager and John R. Gillis* is the president and CEO of SGM Biotech, 10 Evergreen Drive, Suite E, Bozeman, MT 59718, tel. 406.585.9535, fax 406.585.9219,
, http://www.sgmbiotech.com.

*To whom all correspondence should be addressed.

<WEBLINK>
For additional resources and online exclusives on this topic, visit http://pharmtech.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here